KRAS and pancreatic neoplasm: Similarly, Sugimori et al. reported that patients with locally-advanced or metastatic pancreatic cancer whose KRAS mutation in ctDNA remained positive (n = 5) after the initial course of chemotherapy had a significantly worse PFS than those whose ctDNA had disappeared (n = 8) (Sugimori et al. 2020).